Clinical trial · Observational
Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis
Long-term Efficacy of Modified Guilu Erxian Glue in Treating Patients With Myasthenia Gravis: A Retrospective Cohort Study
NCT07472777CI-TRIAL-00105655completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through a retrospective cohort study method, the influence of Gu-Lu Er-Xian Decoction with modified formula on the long-term therapeutic effect of patients with myasthenia gravis was analyzed, and the related factors affecting recurrence were also explored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis (MG) | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- MG patients
Primary outcomes (1)
- measure
- Recurrent rate
- timeFrame
- July 31, 2024
Secondary outcomes (7)
- measure
- The time for the first reduction of conventional Western medicine dosage
- timeFrame
- July 31, 2024
- measure
- MGFA classification
- timeFrame
- July 31, 2024
- description
- Unabbreviated Scale Title: Myasthenia Gravis Foundation of America (MGFA) Clinical Classification for Myasthenia Gravis Scale Range: Class I (ocular-only involvement, mildest) to Class V (mechanical ventilation required, most severe), total 5 hierarchical classes Interpretation: Higher classification grade indicates more severe myasthenia gravis and worse clinical outcome.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Clinically confirmed diagnosis of myasthenia gravis (MG), with other differential diagnoses excluded * Received standardized conventional Western medicine treatment for MG for at least 1 month (bromopyridostigmine tablets combined with prednisone acetate tablets) * Complete and traceable medical records available for the entire study period Exclusion Criteria: * Complicated with other major systemic diseases, severe functional impairment of the heart, liver or kidney, or a documented history of mental illness * Incomplete medical records that cannot support full data extraction and statistical analysis
References
Publications (0)
Data not yet available
No reference posted for this study.